No annual revenue total was found in BridgeBio Oncology Therapeutics, Inc.'s SEC filings.
BridgeBio Oncology Therapeutics, Inc. (BBOT) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$114.5 million. As of Jun 30, 2026 it held $344.1 million in cash and investments and $2.5 million in total debt.
Revenue
—
Net income (TTM)
$-182.11M
-42.2% vs year-ago TTM
Operating cash flow (TTM)
$-151.28M
-55.5% vs year-ago TTM
Free cash flow
$-114.50M
EPS
$-4.30
Dividend per share
None
Shares outstanding
80.03M
Net cash
$341.62M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BBOT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1869105
- Former names
- Helix Acquisition Corp. II (until Aug 6, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$145.8M | -$80.9M |
| Net income | -$134.0M | -$74.3M |
| Diluted EPS | -$4.30 | — |
| Operating cash flow | -$113.9M | -$55.0M |
| Free cash flow | -$114.5M | — |
| Total assets | $448.4M | $164.3M |
| Total liabilities | $37.3M | $19.6M |
| Stockholders' equity | $411.1M | -$178.6M |
| Cash and investments | $425.5M | $185,000 |
| Total debt | $2.8M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 22, 2026 | Jun 16, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
All 184 BridgeBio Oncology Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.